Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab use in patients with multiple sclerosis
RBR-6jhtvfyCompleted
- Sponsor
- Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (UFMS)
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of natalizumab in multiple sclerosis (MS) (2 arms), sponsored by Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (UFMS). Primary endpoint: Quality of life. Started Jun 2022; status: completed.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on RBR-6jhtvfy.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6jhtvfy.